摘要
目的：评价ｒｈＧ－ＣＳＦ（粒生素）对预防恶性肿瘤化疗后粒细胞减少的作用及不良反应。方法：人组总数６３例，均为病理或细胞学证实的恶性肿瘤。采用自身交叉方法将患者随机分入ＡＢ和ＢＡ两组。Ａ为治疗周期，即化疗用药结束４８ｈ开始，每日１次皮下注射ｒｈＧ－ＣＳＦ ５μｇ／ｋｇ，连续用药７～１４ｄ。Ｂ为空白对照周期。自化疗开始隔日查血常规１次，观察中性粒细胞（ＡＮＣ）及白细胞（ＷＢＣ）的变化。结果：治疗组于ｒｈＧ－ＣＳＦ注射２４ｈ后，ＷＢＣ及ＡＮＣ迅速上升，４８ｈ出现第１个高峰，第１０天出现第２个高峰，而对照组化疗后，ＷＢＣ和ＡＮＣ逐渐下降，始终低于治疗组。ＷＢＣ，ＡＮＣ的最低值、ＷＢＣ＜４．０×１０９／Ｌ、ＡＮＣ＜２．０×１０９／Ｌ的持续时间，以及化疗后第２１天ＷＢＣ＜４．０×１０９／Ｌ的病例数在治疗组和对照组间差异有显著性（Ｐ＜０．０５）。结论：ｒｈＧ－ＣＳＦ可以促进化疗患者ＷＢＣ和ＡＮＣ的恢复，耐受性良好，可以作为肿瘤化疗中提高剂量强度的有效辅助药。
Objective: To evaluate the efficacy and side effects of rhG-CSF(recombinant human granulocyte colony stimulating factor) in chemotherapy induced neuteropenia.Methods: 63 cases with malignacies confirmed by pathology or cytology were enrolled. All patients were divided into group AN or BA at randomly self-control cross-over test.At the time of 48 hours after chemotherapy,rhG-CSF was given at a dose of 5 g.kg-1 .d-1 for 7 to 14 days in group A. In group B, the patients received chemotherapy alone without rhG-CSF as control.Bolld routine examination was taken every other day from the start of chemother- apy.The change of absolute neutrophil and neukocyte counts were observed.Results:In the trial group,neutrophil count in- creased rapidly with the first peak after 48 born of rhG-CSF injection. The second peak occurred on the tenth day. In the control group,the absolute neuterophil and leukocyte counts decreased gradually,lower than that of the trial group all the time.There is a significant difference between the trial and control groups (P<0.05) on the nadir of WBC and ANG counts,the duration of WBC<4.0×109/L and ANC<2.0×109/L, and the number of patients with WBC<4.0×109/L on the twenty-first day after chemotherapy.The rates of bone o and local response of injection were 25.8% and 27.4% respectively.Influenzal symptom was infrequent.Conclusion:rhG-CSF plays an important role in accelerating the recovery of leukocyte and absolute neutrophil induced by chemotherapy. The patients were well toleranced. It is suggested that rhG-CSF be a favourably adjuvant drug in the high dose intensive chemotherapy.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
2000年第2期143-145,共3页
Chinese Journal of Cancer Biotherapy
